Epstein-Barr virus-associated lymphoma in Crohn's disease

Inflammatory Bowel Diseases

Volumn 10, Issue 4, 2004, Pages 425-429

  Losco, Alessandra ^a   Gianelli, Umberto ^a   Cassani, Barbara ^a   Baldini, Luca ^a   Conte, Dario ^a   Basilisco, Guido ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; BLEOMYCIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; STEROID; VINCRISTINE;

ADULT; ARTICLE; CANCER RISK; CASE REPORT; CROHN DISEASE; DRUG DEPENDENCE; EPSTEIN BARR VIRUS; HUMAN; ILEOSTOMY; ILEUM DISEASE; INTESTINE LYMPHOMA; INTESTINE PERFORATION; INTESTINE STENOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; PELVIS ABSCESS; PERITONEAL DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS GENE; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GASTROINTESTINAL AGENTS; HERPESVIRUS 4, HUMAN; HUMANS; ILEAL NEOPLASMS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; MALE; POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3543106775     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407000-00015     Document Type: Article

References (44)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015-2019.
3. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population based cohort study. Gastroenterology. 1994;107:1675-1679.
4. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308-2312.
5. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91: 854-862.
6. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985;56:2914-2921.
7. Lewis JD, Bilker WB, Bresinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080 1087.
8. Loftus EV Jr, Sandborn WJ. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001;121: 1239-1242.
9. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343: 1249-1252.
10. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-termtoxicity. Ann Intern Med. 1989; 111:641-649.
11. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
12. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248-3253.
13. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018-1024.
14. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
15. Fraser AG, Orchard TR, Robinson EM, et al. Long term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225-1232.
16. Aithal GP, Mansfield JC. The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther. 2001;15:1101-1108.
17. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972.
18. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999;117:1433-1437.
19. Sachmechian A, Vasiliauskas E, Abreu MT, et al. Malignancy following Remicade therapy: incidence and characteristics. Gastroenterology. 2001;120:A3144.
20. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development. Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
21. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122: 72-77.
22. Hata J, Haruma K, Yamanaka H, et al. Ultrasonographic evaluation of the bowel wall in inflammatory bowel disease: comparison of in vivo and in vitro studies. Abdom Imaging. 1994; 19:395-399.
23. Diss TC, Peng H, Andrew C, et al. Detection of monoclonality in low grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol. 1993;169:291-295.
24. Wright CF, Reid AH, Tsai MM, et al. Detection of Epstein-Barr virus sequences in Hodgkin's disease by the polymerase chain reaction. Am J Pathol. 1991;139:393-398.
25. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101-113.
26. Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738-745.
27. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85:307-311.
28. Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease (letter). N Engl J Med. 1994;331: 883-884.
29. Calaminici MR, Sheaff MT, Norton AJ, et al. Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease. Histopathology. 1999;35:388-389.
30. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease. Am J Surg Pathol. 2000;24:66-73.
31. Li S, Borowitz MJ. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med. 2001;125:424-427.
32. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. Transplantation. 1999;68: 1517-1525.
33. Hirose Y, Masaki Y, Sasaki K, et al. Determination of Epstein-Barr virus association with B-cell lymphomas in Japan: study of 72 cases - in situ hybridization, polymerase chain reaction, immunohistochemical studies. Int J Hematol. 1998;67:165-174.
34. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.
35. Chang KL, Chen YY, Shibata D, et al. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol. 1992;1:246-255.
36. Crisan D, Cadoff EM, Mattson JC, et al. Polymerase chain reaction: amplification of DNA from fixed tissue. Clin Biochem. 1990;23:489-495.
37. Wakefield AJ, Fox JD, Sawyerr AM, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol. 1992;38:183-190.
38. Yanai H, Shimizu N, Nagasaki S, et al. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol. 1999;94: 1582-1586.
39. Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol. 2000;157: 51-57.
40. Windsor ACJ. Ileal Crohn's disease is best treated by surgery. Gut. 2002; 51:11-12.
41. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients, Ann Oncol. 2000;11: S113-S116.
42. Garnier JL, Stevenson G, Blanc-Brunat N, et al. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res. 2002;159:113-122.
43. Berney T, Delis S, Kato T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002;74:1000-1006.
44. Comoli P, Labirio M, Bassi S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592.